Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

Oncology

Volumn 73, Issue 3-4, 2008, Pages 204-209

  Procopio, Giuseppe ^a   Verzoni, Elena ^a   Gevorgyan, Arpine ^a   Mancin, Maddalena ^a   Pusceddu, Sara ^a   Catena, Laura ^a   Platania, Marco ^a   Guadalupi, Valentina ^a   Martinetti, Antonia ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Drug related toxicity; Multikinase inhibitor; Renal cell cancer; Sorafenib

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CONTROL; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BONE NEOPLASMS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRIDINES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE;

EID: 43049120667     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127387     Document Type: Article

References (17)

1. Motzer RJ, Bander NH, Nanus DM: Renal cell carcinoma. N Engl J Med 1996;335:865-875.
2. Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl Cancer 1997;21:185-232.
3. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-463.
4. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear histology. J Clin Oncol 2002;20:2376-2381.
5. Waters JS, Moss C, Pyle L, James M, Hackett S, A'hern R, Gore M, Eisen T: Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91:1763-1768.
6. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-1935.
7. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132.
8. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998;338:1272-1278.
9. Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group: Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;3:220-227.
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
11. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-334.
12. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
13. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007;356:125-134.
15. Bukowski RM, Eisen T, Szczylik C, et al: Final results of randomizes phase III trial of sorafenib in advanced RCC: survival and biomarker analysis. ASCO Proc 2007;25:5023.
16. Ratain MJ, Eckhardt SG: Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-4445.
17. Bajetta E, Procopio G, Verzoni E, Catena L, De Dosso S, Platania M, Gevorgyan A: Renal cell cancer and sorafenib: skin toxicity and treatment outcome. Tumori 2007;93:201-203.